NYSEAMERICAN:SYN Synthetic Biologics (SYN) Stock Price, News & Analysis → (Free Workshop) Advanced “bug-out bag” hacks! (From Warrior Life) (Ad) Free SYN Stock Alerts $1.02 +0.01 (+0.99%) (As of 10/12/2022) Add Compare Share Share Today's Range$0.97▼$1.0250-Day Range N/A52-Week Range$0.97▼$4.56Volume57,700 shsAverage Volume197,338 shsMarket Capitalization$16.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Synthetic Biologics alerts: Email Address Ad Paradigm PressElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Synthetic Biologics Stock (NYSEAMERICAN:SYN)Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.Read More SYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYN Stock News HeadlinesMay 29, 2024 | finance.yahoo.comHigh Throughput Screening Market to Be Worth $47.41 Billion by 2031 - Exclusive Report by Meticulous Research®May 28, 2024 | finance.yahoo.comLeveragen and 92Bio Forge Strategic Alliance to Advance Therapeutics Using Novel Single Domain Antibody PlatformMay 24, 2024 | in.investing.comMidcap stock jumps 4% after company signs supply agreement with Korean based companyMay 23, 2024 | markets.businessinsider.comTheriva: FDA Grants Fast Track Designation To Lead Clinical Candidate VCN-01May 20, 2024 | msn.com8 Trendy Hairstyles To Try This Summer– According To A Celebrity HairstylistMay 15, 2024 | msn.comStages of Rheumatoid ArthritisMay 15, 2024 | benzinga.comThe Analyst Verdict: Absci In The Eyes Of 6 ExpertsMay 14, 2024 | seekingalpha.comHumacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too HighMay 14, 2024 | tmcnet.comNabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein DesignMay 12, 2024 | msn.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comAqtual to Present Data on Innovative Approach to Rheumatoid Arthritis Therapy Selection at CCR East 2024May 2, 2024 | finance.yahoo.comPeptide Synthesis: Global Markets Projected to Reach $157.5 Billion by 2028, According to BCC Research AnalysisApril 30, 2024 | finance.yahoo.comSphere Fluidics Appoints Dale Levitzke as Chief Executive OfficerApril 30, 2024 | finance.yahoo.comEnlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private CapitalApril 29, 2024 | finance.yahoo.comNavigating the Dynamic Landscape of CMO/CDMO Services Market in Today's Pharma Industry; Report by TNR, The Niche ResearchApril 26, 2024 | finance.yahoo.comRegenerative Medicine Market Size Expected to Reach USD 154.05 Bn by 2033April 24, 2024 | finance.yahoo.comGenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug DiscoveryApril 23, 2024 | finance.yahoo.comActive Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4%April 23, 2024 | markets.businessinsider.comTheriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular RetinoblastomaApril 22, 2024 | msn.comElon Musk rejects Tucker Carlson’s viral alien conspiracy theoryApril 19, 2024 | markets.businessinsider.comAziyo Biologics Poised for Growth: Buy Rating Affirmed Amidst Anticipated FDA Clearance and Strong Financial OutlookApril 17, 2024 | finance.yahoo.comX-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)April 17, 2024 | finance.yahoo.comMustGrow Biologics to Present at the Planet MicroCap ShowcaseApril 10, 2024 | msn.com31 Netizens Share What They Consider To Be Next Big Changes In The Culture Of The InternetApril 7, 2024 | businesswire.comAffini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR ...See More Headlines Receive SYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:SYN CUSIPN/A CIK894158 Webwww.syntheticbiologics.com Phone(301) 417-4364Fax301-417-4367Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.14% Return on Assets-22.74% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / Book0.21Miscellaneous Outstanding Shares15,844,000Free Float15,503,000Market Cap$16.16 million OptionableNot Optionable Beta1.38 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Steven A. Shallcross CPA (Age 61)CEO, CFO, Treasurer, Corp. Sec. & Director Comp: $976.91kDr. Frank Tufaro Ph.D. (Age 67)Chief Operating Officer Vincent I. PerroneDirector of Corp. CommunicationDr. Vince WacherHead of Product and Corp. Devel.Dr. Michael KalekoSr. VP of R&DMs. Lara M. GuzmanSr. Director of Project OperationsMore ExecutivesKey CompetitorsSernovaOTCMKTS:SEOVFHillstream BioPharmaNASDAQ:HILSLantern PharmaNASDAQ:LTRNAEON BiopharmaNASDAQ:AEONLeap TherapeuticsNASDAQ:LPTXView All Competitors SYN Stock Analysis - Frequently Asked Questions How were Synthetic Biologics' earnings last quarter? Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. When did Synthetic Biologics' stock split? Synthetic Biologics's stock reverse split before market open on Monday, July 25th 2022. The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthetic Biologics investors own include Synergy Pharmaceuticals (SGYP), Tonix Pharmaceuticals (TNXP), Agenus (AGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), How do I buy shares of Synthetic Biologics? Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:SYN) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synthetic Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.